Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02814916 · ClinicalTrials.gov registry record · Phase 3
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 199
- Enrollment target
NCT02814916 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 199 participants.
The verdict
NCT02814916, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 199 participants
- Enrollment target
Study Summary
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
Interventions
- DRUG Vancomycin
- DRUG Dalbavancin
- DRUG Cefadroxil
- DRUG Oxacillin
- DRUG Flucloxacillin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02814916
The ClinicalTrials.gov registry entry for NCT02814916 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vancomycin is the first listed.
NCT02814916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02814916 about?
NCT02814916 is a clinical study titled "Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA". To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of ...
What is the current status of trial NCT02814916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 199 participants. The study started on 2017-03-30. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT02814916?
The interventions under investigation include: Vancomycin (DRUG), Dalbavancin (DRUG), Cefadroxil (DRUG), Oxacillin (DRUG), Flucloxacillin (DRUG).
Who is sponsoring clinical trial NCT02814916?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.